SPR-206 is a small molecule commercialized by Everest Medicines, with a leading Phase I program in Acinetobacter Infections. According to Globaldata, it is involved in 5 clinical trials, of which 4 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of SPR-206’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SPR-206 is expected to reach an annual total of $66 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SPR-206 is under develoment for the treatment of gram-negative bacterial infections including Acinetobacter baumanii and Pseudomonas aeruginosa and Carbapenem-resistant Enterobacteriaceae infection, complicated urinary tract infections, hospital acquired pneumonia, ventilator associated pneumonia and bloodstream infections. The drug candidate is a polymyxin derivative. It is administered through intravenous route. The drug candidate acts by targeting cell membrane protein lipopolysaccharide.
Everest Medicines Overview
Everest Medicines is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardiorenal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY12.8 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY0.1 million in FY2021. The operating loss of the company was CNY256.8 million in FY2022, compared to an operating loss of CNY1,026.3 million in FY2021. The net loss of the company was CNY247.3 million in FY2022, compared to a net loss of CNY1,008.7 million in FY2021.
For a complete picture of SPR-206’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.